Best Peptides for Weight Loss
Six weight loss peptides ranked by clinical evidence — from FDA-approved GLP-1 agonists to research-grade compounds.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
For weight loss, GLP-1 receptor agonists are the most evidence-backed peptides: tirzepatide outperforms semaglutide in head-to-head data, and retatrutide leads on efficacy (25.0% mean weight loss at 80 weeks in Phase 3 TRIUMPH-1, not yet FDA-approved). All effective options require ongoing use, alongside diet and exercise.
Weight Loss by the Numbers
Clinical trial data tells a clear story: GLP-1 agonists dominate weight loss outcomes. Here's how the peptides compare on their primary efficacy measure — percentage of body weight lost:
Cross-trial comparison caveat: These numbers come from different trials with different populations, durations, and endpoints. Direct comparison is approximate. The only head-to-head data is SURMOUNT-5 (tirzepatide vs semaglutide), which confirmed tirzepatide's superiority.
Rankings by Evidence Strength
Tirzepatide (Mounjaro® / Zepbound®)
Tirzepatide targets both GLP-1 and GIP receptors (a dual-agonist approach). The SURMOUNT-1 trial (n=2,539; PMID 35658024) reported 20.9% mean body weight loss at the 15mg dose over 72 weeks versus 3.1% on placebo (treatment-regimen estimand).
In the open-label head-to-head SURMOUNT-5 trial (n=751; PMID 40353578), tirzepatide at its maximum tolerated dose (10 or 15mg) produced 20.2% mean weight loss at 72 weeks vs 13.7% with semaglutide (1.7 or 2.4mg; P<0.001).
Semaglutide (Wegovy® / Ozempic®)
The drug that launched the GLP-1 revolution. Semaglutide 2.4mg produced 14.9% weight loss in STEP 1 (n=1,961, 68 weeks; PMID 33567185). It also has cardiovascular outcome data: in the SELECT trial (PMID 37952131), semaglutide lowered major adverse cardiovascular events versus placebo (6.5% vs 8.0%; hazard ratio 0.80) in adults with overweight or obesity and preexisting cardiovascular disease.
Retatrutide
The triple-agonist approach adds glucagon receptor activation (increases energy expenditure) to the dual GIP/GLP-1 mechanism. Phase 3 TRIUMPH-1 (NEJM 2026, PMID 42814954) reported a 25.0% mean weight loss at the 12mg dose over 80 weeks versus 3.9% on placebo (treatment-regimen estimand), above the 24.2% at 48 weeks from the Phase 2 trial (n=338; PMID 37366315).
TRIUMPH-1 has reported; the broader Phase 3 program continues. Not yet FDA-approved as of mid-2026.
Tesamorelin (Egrifta®)
Tesamorelin stimulates growth hormone release and is FDA-approved specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy. Its target is visceral fat rather than the number on the scale — it's a body composition drug, not a weight loss drug.
CJC-1295 / Ipamorelin
CJC-1295 is a long-acting GHRH analog: in healthy adults it produced sustained, dose-dependent increases in growth hormone and IGF-I levels (PMID 16352683). Whether the combination with ipamorelin reduces body fat or body weight has not been tested in controlled trials, so any fat-loss effect is unquantified.
It is usually marketed as a body composition tool, often used alongside a caloric deficit and resistance training program.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that was hypothesized to promote fat metabolism without GH's side effects. However, there is no strong clinical evidence that it produces meaningful weight loss in humans.
Not recommended as a primary weight loss peptide based on current evidence.
Self-Assessment
Who Researches Weight Loss Peptides?
This Research Is Commonly Explored By People Who...
- Want a comprehensive comparison of all peptides studied for weight management in one place
- Are trying to understand the differences between GLP-1, GIP, and growth hormone peptide mechanisms
- Have been overwhelmed by marketing claims and want to see what the actual clinical data shows
- Are discussing options with a healthcare provider and want to be an informed participant
- Are interested in both approved therapies and research-stage compounds for context
This Research May Not Be Relevant If...
- You're looking for a specific recommendation — this is a research comparison, not a prescription guide
- You want to self-administer peptides without medical oversight — we strongly advise against this
- You have no weight-related health concerns and are looking for cosmetic enhancements
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)
Key Takeaways
What's Clear
- GLP-1 agonists are the gold standard for weight loss
- Tirzepatide > semaglutide in head-to-head data
- Retatrutide: 25.0% mean weight loss in Phase 3 TRIUMPH-1 (treatment-regimen estimand, PMID 42814954; cross-trial rankings are approximate; not yet FDA-approved)
- Research GH peptides (CJC-1295/Ipamorelin, AOD-9604) lack strong clinical evidence for weight loss
- All effective options require ongoing use to maintain
- Diet + exercise still matter alongside any peptide
Important Caveats
- Cross-trial comparisons are approximate
- Individual response varies dramatically
- Part of the weight lost can be lean mass (muscle)
- Weight regain after discontinuation is significant
- Long-term safety data still accumulating
- Cost and insurance coverage vary widely
Weight Loss Support
Tools to maximize your weight loss results
Affiliate links support HighPeptides at no extra cost.
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.